Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer.

The Prostate - 1 Dec 2008

Scariano John K, Treat Eric, Alba Frances, Nelson Harold, Ness Scott A, Smith Anthony Y

Abstract excerpt

BACKGROUND: Emerging evidence indicates that testosterone (T), and not dihydrotestosterone (DHT), is the most relevant androgen that promotes carcinogenesis in the prostate. Steroid 5-alpha reductase type II (SRD5A2) catalyzes the irreversible conversion of T to DHT in male reproductive organs. B...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 3-Oxo-5-alpha-Steroid 4-Dehydrogenase
Share to Adenocarcinoma
Share to Age of Onset

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to Gene Expression Regulation, Neoplastic

Share to Pilot Projects

Share to Prostatic Neoplasms

Share to Severity of Illness Index

Source

Identifiers

PMID: 18780294
DOI: 10.1002/pros.20842

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-18780294-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer.PMID 18780294Read ↗

Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR.Semantic proximity Read ↗

SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness.Semantic proximity Read ↗

Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.Semantic proximity Read ↗

SRD5A2 V89L polymorphism and prostate cancer risk: a meta-analysis.Semantic proximity Read ↗

A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase.Semantic proximity Read ↗

Polymorphism of the SRD5A2 gene and the risk of prostate cancer.Semantic proximity Read ↗

V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression.Semantic proximity Read ↗

Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.Semantic proximity Read ↗

Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.Semantic proximity Read ↗

5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia.Semantic proximity Read ↗

Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population.Semantic proximity Read ↗

Editorial comment on: Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.